Articles
Latest Articles
Evidence-based analysis and clinical commentary on peptide therapeutics — updated as the literature evolves. · 29 articles
What Serious Adverse Event Categories Have Been Reported After Compounded BPC-157 Injections — Immune Reactions, Liver Signals, Allergic Events, and Tumor-Growth Risk — in 2026?
As of 2026, serious adverse events reported after compounded BPC-157 injections span four clinical categories: immune-mediated reactions driven by peptide immunogenicity, allergic and anaphylactoid responses from parenteral exposure, hepatic signals that remain mechanistically unresolved, and a theoretical tumor-growth risk grounded in BPC-157's pro-angiogenic activity. No controlled human trial has characterised the incidence or causation of any category.
How Should Clinicians Assess Causality, Dose Uncertainty, and Product Quality When a Patient Reports an Adverse Event After Non-Approved BPC-157 Use in 2026?
When a patient presents with a suspected adverse event after non-approved BPC-157 use in 2026, clinicians face three compounding uncertainties: causality cannot be established through standard dechallenge-rechallenge logic, the administered dose is unverifiable, and the product may contain immunogenic impurities unrelated to BPC-157's intrinsic pharmacology. Structured causality tools, dose reconstruction, and product-quality interrogation are the three assessment pillars.
Why Did the FDA's Pharmacy Compounding Advisory Committee Vote Yes on Six Peptides in 2026 When Agency Scientists Concluded the Evidence Was Insufficient?
At the July 2026 PCAC meeting, the FDA's advisory committee voted to recommend six peptides — BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax — for the 503A bulk compounding list. FDA career scientists had concluded all seven substances were inadequately characterised and lacked sufficient human safety and efficacy evidence. The committee majority weighted clinical need over the staff's evidence threshold.
What Does 2026 Research Reveal About Current Trends in Semaglutide Therapy and Strategies to Improve Its Oral Bioavailability?
A 2026 review by Nayak et al. in Expert Opinion on Drug Delivery identifies oral bioavailability as semaglutide's central unresolved limitation, with approved oral Rybelsus® achieving only ~0.4–1% absolute bioavailability via the SNAC mechanism. The review catalogues novel strategies — lipid nanoparticles, SNEDDS, mucoadhesive polymers, and ionic liquid complexation — designed to overcome gastric acid degradation and first-pass proteolysis.
Can Avexitide Reduce Post-Bariatric Hypoglycemia Through GLP-1 Receptor Antagonism, and What Did the 2026 Phase 3 LUCIDITY Trial Show?
Yes. Avexitide — a competitive GLP-1 receptor antagonist derived from the truncated exendin-(9-39) peptide — reduces post-bariatric hypoglycemia by blocking the exaggerated postprandial GLP-1 signal driving pathological insulin secretion after Roux-en-Y gastric bypass. The 78-participant phase 3 LUCIDITY trial (August 2026) met its FDA-agreed primary endpoint: a 55% reduction in composite Level 2 and Level 3 events versus placebo (p=0.000003).
Why Did the EVOKE Trial Design Structurally Fail to Test Semaglutide's Neuroprotective Hypothesis in 2026, and What Would a Valid Prevention Trial Require?
The 2026 Alhowail review in Frontiers in Aging Neuroscience concludes that the EVOKE Phase 3 trials were structurally mismatched to semaglutide's neuroprotective hypothesis across three dimensions: oral delivery producing CNS underexposure, population selection in patients with established pathology, and a clinical endpoint insensitive to metabolic stabilisation. A valid prevention trial requires subcutaneous dosing, cognitively normal at-risk participants, and biomarker-primary endpoints.
When Ten Serious Adverse Events Exist but Zero Controlled Human Efficacy Trials Do, What Does the BPC-157 Evidence Record Actually Tell Us in 2026?
As of 2026, the BPC-157 evidence record presents a structural asymmetry: ten serious adverse event reports filed with the FDA's Adverse Event Monitoring System since 2021 — eight of them in 2026 alone — exist alongside zero completed, peer-reviewed, randomised controlled human efficacy trials. That asymmetry fundamentally limits what either dataset can be interpreted to mean.
Does the Epidemiological Signal for Semaglutide and Dementia Risk Survive Methodological Scrutiny in 2026?
The epidemiological signal is consistent but not causally established. Across six independent cohort studies through 2026, semaglutide users with type 2 diabetes show 40 to 70 percent lower dementia incidence versus comparator antidiabetic agents. Active-comparator designs reduce but cannot eliminate confounding; the negative EVOKE Phase 3 trials introduce an interpretive tension the 2026 Alhowail review frames as a population-timing mismatch.
Are Glutathione Injections and IV Infusions Linked to Contaminated-Product Illnesses in 2026?
Yes. A 2026 CDC multistate investigation confirmed more than 25 illnesses, including hospitalizations, linked to compounded injectable glutathione with elevated bacterial endotoxin. Four Texas compounding pharmacies issued nationwide recalls between August and October 2026. The root cause was dietary supplement-grade glutathione used as a starting ingredient, which does not meet sterility or endotoxin standards for injectable drug manufacturing.
What Is the Current Human Safety Signal for BPC-157 in Unapproved Injection Products in 2026?
As of September 2026, the human safety signal for BPC-157 in unapproved injection products is escalating but incompletely characterised. A real-world pharmacovigilance preprint documented a 33-fold rise in confirmed users between 2020 and 2026. The FDA's Adverse Event Monitoring System recorded 10 serious adverse event reports since 2021, with 8 filed in 2026 alone. BPC-157 holds no FDA approval.
Does Catestatin Peptide Reduce Tau, Amyloid, and Neuroinflammation in Preclinical Alzheimer's Disease Models in 2026?
In preclinical models studied through 2026, catestatin (CST) — a 21-amino-acid peptide derived from chromogranin A — reduces tau hyperphosphorylation and aggregation, lowers amyloid plaque burden, suppresses glial neuroinflammation, and restores both cognitive and motor function. All evidence is from rodent models; no human clinical trials have been initiated as of 2026.
How Does Semaglutide's GLP-1R/SIRT1 Axis Address Brain Insulin Resistance as a Metabolic Root of Cognitive Decline in 2026?
The 2026 Alhowail review in Frontiers in Aging Neuroscience frames brain insulin resistance — not amyloid burden alone — as the upstream metabolic lesion that semaglutide's GLP-1R/SIRT1/GLUT4 axis is best positioned to correct. Preclinical data show restored cerebral glucose uptake, suppressed NLRP3 inflammasome activation, and attenuated tau hyperphosphorylation, but human prevention trials in at-risk populations remain the critical missing evidence.